Gene Therapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
Semin Oncol. 2011 Dec;38(6):776-80. doi: 10.1053/j.seminoncol.2011.08.004.
Lung cancer still represents a very deadly disease in strong need of new, effective, therapeutic approaches. MicroRNAs (miRNAs) represent a new category of noncoding RNAs with gene expression regulatory functions. Several studies have shown that miRNAs are frequently deregulated in lung cancer patients with respect to healthy individuals. These aberrations of the miRNome (defined as the full spectrum of miRNAs in a given genome) occur at several levels, including primary tumors and patient body fluids (such as blood and sputum), suggesting that miRNAs can be effectively used as biological markers with diagnostic, prognostic, and predictive implications. This review focuses on these translational aspects of research on the field of miRNAs and lung cancer.
肺癌仍然是一种非常致命的疾病,非常需要新的、有效的治疗方法。微小 RNA(miRNA)是一类具有基因表达调控功能的新型非编码 RNA。多项研究表明,与健康个体相比,肺癌患者的 miRNA 经常失调。这些 miRNA 组(定义为给定基因组中所有 miRNA 的总和)的异常发生在多个水平上,包括原发性肿瘤和患者的体液(如血液和痰液),表明 miRNA 可以作为具有诊断、预后和预测意义的生物标志物进行有效利用。本综述重点介绍了 miRNA 和肺癌领域研究的这些转化方面。